Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis

被引:15
|
作者
Trilling, B. [1 ,2 ]
Cotte, E. [2 ,3 ]
Vaudoyer, D. [2 ]
Isaac, S. [4 ]
Piaton, E. [5 ]
Maurice, C. [6 ]
Glehen, O. [2 ,3 ]
Passot, G. [2 ,3 ]
机构
[1] Clin Chirurg Viscerale & Urgence, Grenoble Alpes, France
[2] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Chirurg Gen Digest & Cancerol, Pierre Benite, France
[3] Univ Lyon 1, EMR 37 38, F-69365 Lyon, France
[4] CHU Lyon Sud, Serv Anat & Cytol Pathol, Lyon, France
[5] CHU Edouard Herriot, Ctr Pathol Est, Lyon, France
[6] Hosp Civils Lyon, Pole IMER, Unite Rech Clin, Lyon, France
关键词
Intraperitoneal-free cancer cells; Colorectal carcinomatosis; Overall survival; Prognosis; COMPLETE CYTOREDUCTIVE SURGERY; LAVAGE CYTOLOGY; OVARIAN-CANCER; CHEMOTHERAPY; DISSEMINATION; RESECTION; RISK; COMBINATION; CATUMAXOMAB; RECURRENCE;
D O I
10.1097/DCR.0000000000000589
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Intraperitoneal-free cancer cells are considered as an important prognostic tool in gastric and ovarian cancer. However, their significance in colorectal cancer remains more controversial. OBJECTIVE: This study aimed to determine the role of intraperitoneal-free cancer cells as a prognostic tool in the outcome in colorectal peritoneal carcinomatosis treated with curative intent by complete cytoreductive surgery. DESIGN: This study is an analysis of a prospectively maintained database. PATIENTS: Between 1991 and 2012, all patients treated in a single institution for colorectal peritoneal carcinomatosis by complete cytoreductive surgery with peritoneal cytology available were evaluated. Peritoneal cytology was stained in the conventional way (May Grumwald Giemsa). RESULTS: Among a population of 162 patients treated for colorectal peritoneal carcinomatosis by complete cytoreductive surgery, 38 presented positive intraperitoneal-free cancer cells (23.5%). Systemic chemotherapy was administered to 135 patients (85%) during the preoperative course. Median follow-up was 34.5 months. Median overall survival was 19 and 44 months for positive and negative intraperitoneal-free cancer cells (p = 0.018). In multivariate analysis, Peritoneal Carcinomatosis Index and positive intraperitoneal-free cancer cells were significant prognostic factors of overall survival (HR, 2.3 (1.18-4.52), p = 0.014; HR, 1.9 (1.08-3.38), p = 0.027). LIMITATIONS: Retrospective analysis and the long period were limitations of study. CONCLUSION: Along with the Peritoneal Carcinomatosis Index, intraperitoneal-free cancer cells are a strong prognostic factor for patients treated with curative intent for colorectal peritoneal carcinomatosis by complete cytoreductive surgery. The presence of intraperitonealfree cancer cells should lead to the consideration of different treatment strategies such as extensive intraperitoneal lavage, targeted intraperitoneal therapies, or repeated intraperitoneal chemotherapy.
引用
收藏
页码:615 / 622
页数:8
相关论文
共 50 条
  • [1] INTRAPERITONEAL-FREE CANCER CELLS REPRESENT A MAJOR PROGNOSTIC FACTOR IN COLORECTAL PERITONEAL CARCINOMATOSIS.
    Trilling, B.
    Cotte, E.
    Vaudoyer, D.
    Glehen, O.
    Passot, G.
    DISEASES OF THE COLON & RECTUM, 2016, 59 (05) : E196 - E196
  • [2] Regimens of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer
    Murono, Koji
    Kawai, Kazushige
    Hata, Keisuke
    Emoto, Shigenobu
    Kaneko, Manabu
    Sasaki, Kazuhito
    Nishikawa, Takeshi
    Otani, Kensuke
    Tanaka, Toshiaki
    Nozawa, Hiroaki
    ANTICANCER RESEARCH, 2018, 38 (01) : 15 - 22
  • [3] Intraperitoneal hyperthermic chemotherapy as treatment of peritoneal carcinomatosis of colorectal cancer
    Markman, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1527 - 1527
  • [4] Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer
    Behrenbruch, Corina
    Hollande, Frederic
    Thomson, Benjamin
    Michael, Michael
    Warrier, Satish K.
    Lynch, Craig
    Heriot, Alexander
    ANZ JOURNAL OF SURGERY, 2017, 87 (09) : 665 - 670
  • [5] Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer
    Ji, Zhong-He
    Peng, Kai-Wen
    Li, Yan
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 1
  • [6] Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
    Chandler, Christopher S.
    Bell, Meghan M.
    Chung, Sebastian K.
    Veach, Darren R.
    Fung, Edward K.
    Punzalan, Blesida
    Vargas, Daniela Burnes
    Patel, Mitesh
    Xu, Hong
    Guo, Hong-fen
    Santich, Brian H.
    Zanzonico, Pat B.
    Monette, Sebastien
    Nash, Garrett M.
    Cercek, Andrea
    Jungbluth, Achim
    Pandit-Taskar, Neeta
    Cheung, Nai Kong, V
    Larson, Steven M.
    Cheal, Sarah M.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (01) : 125 - 137
  • [7] Heated intraperitoneal chemotherapy for peritoneal carcinomatosis from colon cancer: Prognostic factor analysis on 46 patients
    Karimdjee, F.
    Bereder, J.
    Beniziri, E.
    Sautot-Vial, N.
    Habre, J.
    Rahili, A.
    Bernard, J.
    Mounier, N.
    Benchimol, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study
    Kozman, Mathew A.
    Fisher, Oliver M.
    Rebolledo, Bree-Anne J.
    Parikh, Roneil
    Valle, Sarah J.
    Arrowaili, Arief
    Alzahrani, Nayef
    Liauw, Winston
    Morris, David L.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (04) : 725 - 736
  • [9] CYTOREDUCTIVE SURGERY AND INTRAPERITONEAL CHEMOTHERAPY FOR COLORECTAL PERITONEAL CARCINOMATOSIS
    Akbarov, E. T.
    Navruzov, S. N.
    Boboqulov, H. B.
    ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135
  • [10] Colorectal cancer and peritoneal carcinomatosis
    Cintron, JR
    Pearl, RK
    SEMINARS IN SURGICAL ONCOLOGY, 1996, 12 (04): : 267 - 278